181 results on '"Scheen, Andre J."'
Search Results
2. Weight loss therapy and addiction: Increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists
3. Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease: Underuse of GLP-1RAs in patients with ASCVD
4. Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review
5. Metformin, Sulfonylureas, DPP-4 Inhibitors and Cardiovascular Outcomes in Type 2 DM
6. Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
7. Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
8. Double et triple agonistes : rôle du glucagon
9. Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
10. Comparative effects between old and new antidiabetic agents on metabolic- associated fatty liver disease (MAFLD)
11. Use of SGLT2 inhibitors after bariatric/metabolic surgery: Risk/benefit balance
12. Metabolic disorders induced by psychotropic drugs
13. Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes: SGLT2 inhibitors in elderly and real life
14. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes
15. Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
16. Clinical pharmacology of antidiabetic drugs: What can be expected of their use?
17. Glucagon, from past to present: a century of intensive research and controversies
18. Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors
19. Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
20. Dissecting the reduction in cardiovascular death with SGLT2 inhibitors: Potential contribution of effects on ventricular arrhythmias and sudden cardiac death?
21. Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: A meta-analysis of observational studies
22. Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers
23. Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?
24. Médicaments anti-obésité : leçons des échecs pour l’avenir
25. The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection
26. Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
27. Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies
28. Epidemiology of acute kidney injury adverse events with SGLT2 inhibitors: A meta-analysis of observational cohort studies
29. Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors?
30. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
31. Sulphonylureas in the management of type 2 diabetes: To be or not to be?
32. Obésité et COVID-19 : le choc fatal entre deux pandémies
33. Series: Implications of the recent CVOTs in type 2 diabetes: Impact on guidelines: The endocrinologist point of view
34. Sodium–glucose co-transporter type-2 inhibitors for hospitalised patients with COVID-19: safe but not protective
35. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
36. Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists
37. L'épopée des insulines des années 1930 aux années 1980
38. Cibler la voie métabolique du cortisol comme action thérapeutique dans le diabète de type 2
39. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
40. Precision medicine: The future in diabetes care?
41. Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis
42. Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation
43. Traitement pharmacologique du diabète de type 2 après chirurgie bariatrique/métabolique
44. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes
45. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes
46. Les inhibiteurs des SGLT2 réduisent le risque de fibrillation auriculaire, d’arythmies ventriculaires et de mort subite
47. Nutritional Counseling for Overweight Patients and Patients with Metabolic Syndrome
48. GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?
49. Cardiovascular risk factors and complications associated with albuminuria and impaired renal function in insulin-treated diabetes
50. Quels bénéfices antitumoraux attendre de la metformine ?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.